The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia. TEL-mediated oligomerization of JAK2 results in constitutive activation of the tyrosine kinase (JH1) domain and confers cytokine-independent proliferation on interleukin-3-dependent Ba/F3 cells. Forced expression of the JAK inhibitor gene SOCS1/JAB/SSI-1 induced apoptosis of TEL-JAK2-transformed Ba/F3 cells. This suppression of TEL-JAK2 activity was dependent on SOCS box-mediated proteasomal degradation of TEL-JAK2 rather than on kinase inhibition. Degradation of JAK2 depended on its phosphorylation and its high affinity binding with SOCS1 through the kinase inhibitory region and the SH2 domain. It has been demonstrated that von Hippel-Lindau disease (VHL) tumor-suppressor gene product possesses the SOCS box that forms a complex with Elongin B and C and Cullin-2, and it functions as a ubiquitin ligase. The SOCS box of SOCS1/JAB has also been shown to interact with Elongins; however, ubiquitin ligase activity has not been demonstrated. We found that the SOCS box interacted with Cullin-2 and promoted ubiquitination of TEL-JAK2. Furthermore, overexpression of dominant negative Cullin-2 suppressed SOCS1-dependent TEL-JAK2 degradation. Our study demonstrates the substrate-specific E3 ubiquitin-ligase-like activity of SOCS1 for activated JAK2 and may provide a novel strategy for the suppression of oncogenic tyrosine kinases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ablation of TCEB2, a binding partner of SOCS1, also improved tumor clearance, suggesting that the SOCS1/TCEB2 complex restrains T cell responses and is a potential target for immunotherapy (Ilangumaran et al., 2017; Kamizono et al., 2001; Liau et al., 2018).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Kamizono et al., 2001
Citations
Cites
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408
Self-citationStructure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase
Joazeiro, C. A. P., Wing, S. S., Huang, H.-K., Leverson, J. D., Hunter, T., & Liu, Y.-C. (1999) · Science · doi:10.1126/science.286.5438.309 · Cited by 1,034
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80047-1 · Cited by 762
Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07281.x · Cited by 753
Self-citationTwenty proteins containing a C-terminal SOCS box form five structural classes
Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., Starr, R., Nicholson, S. E., Metcalf, D., & Nicola, N. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.114 · Cited by 733
Research works printed but not linked: 1
- Shuai, 1996, Oncogene, 13, 247
Cited by
Items 201–300 of 314
Qin, T., Wu, Y., Liu, T., & Wu, L. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03180-3 · Cited by 28
“After STAT3 is activated by cytokines, the STAT3 dimer is transported to downstream target genes of nuclear induction, including SOCS [30].”
BackgroundRetrograde activation of STAT3 by leukemia inhibitory factor in sympathetic neurons
OʼBrien, J., & Nathanson, N. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04736.x · Cited by 29
“In particular, the suppressors of cytokine signaling 1 is thought be involved in the targeting of Jak for ubiquitiation and ultimately proteosomal degradation (Kamizono et al. 2001; Kile and Alexander 2001; Wormald and Hilton 2003).”
BackgroundDifferential regulation of Toll‐like receptor signalling in spleen and Peyer’s patch dendritic cells
Davies, J. M., MacSharry, J. A., & Shanahan, F. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03317.x · Cited by 30
Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Lamsoul, I., Uttenweiler‐Joseph, S., Moog‐Lutz, C., & Lutz, P. G. (2015) · Biochimie · doi:10.1016/j.biochi.2015.08.003 · Cited by 26
Elongin B/C Recruitment Regulates Substrate Binding by CIS*
Piessevaux, J., Ceuninck, L. D., Catteeuw, D., Peelman, F., & Tavernier, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803742200 · Cited by 29
Janus kinase 3: the controller and the controlled
Wu, W. D., & Sun, X.-H. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr105 · Cited by 28
“The SOCS box in SOCS1 has been demonstrated to be essential for the association of SOCS1 with the Elongin B/C complex as well as ubiquitination of JAK2 [50].”
BackgroundIlangumaran, S., Finan, D., Rose, J. L., Raine, J. C., Silverstein, A., Sepulveda, P. D., & Rottapel, R. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5010 · Cited by 31
“SOCS1 have been shown to be targeted for ubiquitin-dependent proteasomal degradation, a process that requires an intact SOCS box (30, 31).”
BackgroundSOCS1 negatively regulates the production of Foxp3+ CD4+ T cells in the thymus
Zhan, Y., Davey, G. M., Graham, K., Kiu, H., Dudek, N., Kay, T., & Lew, A. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.23 · Cited by 32
Ubiquitin-mediated regulation of JAK-STAT signaling in embryonic stem cells
Hatakeyama, S. (2012) · JAK-STAT · doi:10.4161/jkst.21560 · Cited by 27
“SOCS1 mediates ubiquitination of JAK2 and TEL-JAK2 oncogene dependent on a SOCS-box.(83,84) SOCS3 induces proteasomedependent degradation of target receptors including CD33 and sialic-binding immunoglobulin-like lectin (Siglec) 7.”
BackgroundSelf-citationLi, B., Yang, F., Clapp, D. W., & Chun, K. T. (2003) · Blood · doi:10.1182/blood-2002-05-1517 · Cited by 25
Jung, S., Kim, S., & Lee, C. (2016) · Oncotarget · doi:10.18632/oncotarget.11537 · Cited by 24
“SOCS1 inhibition of Jak is known to involve molecular interaction of SOCS1 with tyrosine phosphorylated Jak [33, 35].”
BackgroundHromadová, D., Elewaut, D. S., Inman, R. D., Strobl, B., & Gracey, E. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.685280 · Cited by 25
“…suppressor of cytokine signaling (SOCS) family, which can specifically block kinase activity of JAK (Liau et al., 2018), block STAT docking (Yamamoto et al., 2003) and can also target the activated cytokine receptor for degradation via ubiquitination (Kamizono et al., 2001; Durham et al., 2019).”
BackgroundGuo, C.-J., Yang, L., Zhang, Y.-F., Wu, Y., Weng, S., Yu, X., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041092 · Cited by 25
“SOCS1 promoted the ubiquitination and proteasomal degradation of TEL-Jak2 fusion protein in a SOCS box-dependent fashion [17].”
BackgroundSOCS proteins in T helper cell differentiation: implications for allergic disorders?
Inoue, H., & Kubo, M. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404008348 · Cited by 26
DCNL1 Functions as a Substrate Sensor and Activator of Cullin 2-RING Ligase
Heir, P., Sufan, R. I., Greer, S. N., Poon, B., Lee, J. E., & Ohh, M. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01342-12 · Cited by 24
“Other substrate receptors of the CRL family including SOCS1 (another CUL2-based CRL) and SOCS2 (CUL5-based CRL) (39, 40) were also capable of binding DCNL1 (see Fig.”
BackgroundColonne, P. M., Sahni, A., & Sahni, S. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.054502-0 · Cited by 23
“SH2 domains of SOCS proteins, on the other hand, inhibit IFN signalling by competing with STATs for the receptor binding sites, inhibiting JAKs by direct binding, or by targeting bound proteins for proteasomal degradation (Kamizono et al., 2001; Kile et al., 2002).”
BackgroundBudroni, V., & Versteeg, G. A. (2021) · Viruses · doi:10.3390/v13040584 · Cited by 21
“In line with the notion that even in myeloid cells with higher steady-state levels, negative feedback loops resulting in IRF7 degradation are in place, immune-induced SOCS1 has been reported to target IRF7 in TLR-activated human pDCs [9].”
BackgroundInfluentialLuan, X., Yang, W., Bai, X., Li, H., Li, H., Fan, W., Zhang, H., Liu, W., & Sun, L. (2021) · The FASEB Journal · doi:10.1096/fj.202101044rrr · Cited by 21
Chen, Y., Zhong, W., Xie, Z., Li, B., Li, H., Gao, K., & Ning, Z. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198748 · Cited by 21
Stepkowski, S. M., & Kirken, R. A. (2006) · Transplantation · doi:10.1097/01.tp.0000228903.03118.be · Cited by 21
“In the opposite situation, an over-expression of SOCS1 induced reduction of thymocytes (93), and increased apoptosis of T cells in a similar fashion as observed in Jak3- or cdeficient mice (94).”
ResultClahsen, T., Lehmann, U., Stroß, C., Hermanns, H. M., Volkmer, R., Schneider‐Mergener, J., Heinrich, P. C., & Schaper, F. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.09.016 · Cited by 21
Yong, Y.-H., Wang, P., Jia, R., Gooneratne, R., Wang, H.-C. R., Liao, M., & Ju, X. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1541484 · Cited by 20
“SOCS members can also inhibit cytokine signaling by SOCS-box-mediated ubiquitination to induce targeted proteasomal degradation of signaling proteins [15,16].”
BackgroundYoshimura, A., Aki, D., & Ito, M. (2021) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.97.016 · Cited by 20
Self-citationWei, J., Li, M., Wang, D., Zhu, H., Kong, X., Wang, S., Zhou, Y., Ju, Z., Xu, G., & Jiang, G. (2017) · Molecular Pain · doi:10.1177/1744806916688901 · Cited by 19
“One function of the SOCS box is to recruit components of the ubiquitintransferase system and to coordinate their assembly and ability to ubiquitinylate target proteins.(52) TRAF6 protein is also likely a target for SOCS3 proteins.”
BackgroundIn Vivo Selection of Genetically Modified Erythroid Cells Using a Jak2-Based Cell Growth Switch
Zhao, S., Weinreich, M. A., Ihara, K., Richard, R. E., & Blau, C. A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.014 · Cited by 19
SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity
Ilangumaran, S., Gui, Y., Shukla, A., & Ramanathan, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362224 · Cited by 18
Monahan, A., & Starz‐Gaiano, M. (2015) · Mechanisms of Development · doi:10.1016/j.mod.2015.08.003 · Cited by 19
Dagvadorj, J., Naiki, Y., Tumurkhuu, G., Noman, A. S. M., Iftakhar-E-Khuda, I., Komatsu, T., Koide, N., Yoshida, T., & Yokochi, T. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03154.x · Cited by 18
Sitko, J. C., Guevara, C. I., & Cacalano, N. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404007200 · Cited by 22
Kardam, S., Ambasta, R. K., & Kumar, P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102465 · Cited by 19
Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development
Ducker, C. E., & Shaw, P. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105119 · Cited by 18
“In this case, suppressor of cytokine signalling 1 (SOCS1) was shown to interact with CUL-2 and promote ETV6-JAK2 polyubiquitination, which occurred through the JH1 domain independently of the ETV6 portion of the protein [103].”
BackgroundPalianopoulou, M., Papanikolaou, V., Stefanou, N., & Tsezou, A. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010224 · Cited by 16
Cullin-5 Adaptor SPSB1 Controls NF-κB Activation Downstream of Multiple Signaling Pathways
Georgana, I., & de Motes, C. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03121 · Cited by 15
“We also noticed that depletion of SOCS1, a known inhibitor of NF-κB and JAK/STAT signaling (48, 49), did not result in significant changes in NF-κB activation in our screen.”
BackgroundSuppressors of cytokine signaling (SOCS) proteins in inflammatory bone disorders
Santos, M. R. G., Queiroz‐Junior, C. M., Madeira, M. F. M., & Machado, F. S. (2020) · Bone · doi:10.1016/j.bone.2020.115538 · Cited by 15
Modulation of Janus kinase 2 by p53 in ovarian cancer cells
Reid, T., Jin, X., Song, H., Tang, H.-J., Reynolds, R. K., & Lin, J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.169 · Cited by 15
Suppressor of Cytokine Signaling 1 Regulates an Endogenous Inhibitor of a Mast Cell Protease*
Ilangumaran, S., Finan, D., Raine, J., & Rottapel, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308382200 · Cited by 13
Morichika, K., Karube, K., Kayo, H., Uchino, S., Nishi, Y., Nakachi, S., Okamoto, S., Morishima, S., Ohshiro, K., Nakazato, I., et al. (2019) · Cancer Science · doi:10.1111/cas.14114 · Cited by 14
“Sex, male (female) 23 (15) 60 (40) 44 (29) 60 (40)”
Role of suppressor of cytokine signaling in ocular allergy
Kubo, M., Ozaki, A., Tanaka, S., Okamoto, M., & Fukushima, A. (2006) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/01.all.0000244797.48981.6d · Cited by 15
Suppressors of cytokine signaling proteins in innate and adaptive immune responses.
Dalpke, A. H., & Heeg, K. M. (2003) · PubMed · Cited by 16
Hemistepsin a Induces Apoptosis of Hepatocellular Carcinoma Cells by Downregulating STAT3
Cho, I. J., Kim, J. K., Kim, E. O., Park, S. M., Kim, S. C., Ki, S. H., & Ku, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094743 · Cited by 13
“In addition, the suppressor of cytokine signaling protein also recruits the ubiquitindependent proteasome system for degrading targets [36].”
BackgroundKanno, H., Yoshizumi, T., Shinonaga, M., Kubo, A., Murata, H., & Yao, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03506-8 · Cited by 14
“Thus, VHL-JAK-STAT signaling pathway in CNS hemangioblastoma might alternatively play critical roles in proliferation, maintaining stem-cell-nature, angiogenesis and cell cycle promotion [44].”
BackgroundCrystal Structure of Human ASB9-2 and Substrate-Recognition of CKB
Fei, X., Gu, X., Fan, S., Yang, Z., Li, F., Zhang, C., Gong, W., Mao, Y., & Ji, C. (2012) · The Protein Journal · doi:10.1007/s10930-012-9401-1 · Cited by 12
The Negative Regulation of JAK/STAT Signaling
Murphy, J. M., Tannahill, G. M., Hilton, D. J., & Greenhalgh, C. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00064-4 · Cited by 12
Sp2 regulates interferon-γ-mediated socs1 gene expression
Letourneur, M., Valentino, L., Travagli-Gross, J., Bertoglio, J. H., & Pierre, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.05.004 · Cited by 14
STAT and SMAD signaling in cancer.
Iwamoto, T., Oshima, K., Seng, T. J., Feng, X., Oo, M. L., Hamaguchi, M., & Matsuda, S. (2002) · PubMed · doi:10.14670/hh-17.887 · Cited by 14
Aydın, B., Beklen, H., Arğa, K. Y., Bayraklı, F., & Turanlı, B. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01923-2 · Cited by 11
Kausar, S., Gul, I., Liu, R., Ke, X., Dong, Z., Abbas, M. N., & Cui, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810389 · Cited by 11
“The SOCS-box is critical for the recruitment of the E3 ubiquitin ligase scaffold Cullin 5, which then catalyzes the ubiquitination of phosphorylated signaling intermediates bound to the SH2 domain [11,25,26].”
BackgroundVakil, L., Najafipour, R., Rakhshani, N., Zamani, F., Morakabati, A., & Javadi, A. (2016) · Tumor Biology · doi:10.1007/s13277-015-4723-1 · Cited by 11
Gao, Z.-Y., Su, L., Wu, Q., Sheng, J., Wang, Y., Dai, Y., Chen, A., He, S., Huang, X., & Yan, G. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05913-2 · Cited by 10
BC-Box Motif-Mediated Neuronal Differentiation of Somatic Stem Cells
Kanno, H., Xu, Y., Miyakawa, T., Kubo, A., Higashida, T., Kobayashi, N. B., Yoshida, T., & Tanokura, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020466 · Cited by 9
Jiang, R., He, S., Gong, H., Wang, Y., Wei, W., Chen, J., Hu, J., Ye, C., LiuHuang, S., Jin, S., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8441676 · Cited by 10
“SOCS1 was known as an inhibitor of tumor cell growth [42].”
RetractedFei, X., Zhang, Y., Gu, X., Qiu, R., Mao, Y., & Ji, C. (2009) · Protein and Peptide Letters · doi:10.2174/092986609787601688 · Cited by 8
Jensik, P. J., & Arbogast, L. A. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.017 · Cited by 7
“SOCS1 increases the degradation of translocation ets leukemia- Janus kinase 2 (JAK2) fusion protein and insulin receptor substrates 1/ 2 and this activity is dependent on the SOCS box (Kamizono et al., 2001; Rui et al., 2002).”
BackgroundFan, X., Qiu, L., Zhu, W., Huang, L., Tu, X., & Miao, Y. (2023) · Foods · doi:10.3390/foods12040708 · Cited by 6
“bind and target phosphorylated JAK2 for degradation through its E3 ubiquitin-ligase-like activity [34].”
BackgroundZhao, X., Zhao, S., Zheng, G., Zhou, J.-G., & Zou, S. (2019) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2019.113243 · Cited by 6
Zhang, J. ‐., Fan, Y., Zhang, Z. ‐., Han, J., Wang, L., Li, T., Zhang, F., Yin, Y. ‐., Hu, L., Yang, Y., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12286 · Cited by 6
KIAA0317 regulates SOCS1 stability to ameliorate colonic inflammation
Lockwood, K. C., Lear, T., Rajbhandari, S., McKelvey, A. C., Dunn, S. R., Boudreau, Á. N., Liu, Y., & Chen, B. B. (2023) · FEBS Journal · doi:10.1111/febs.16780 · Cited by 5
Regulation of JAKs: Insights Gleaned from the Functional Protein Domains
Haan, C., Ungureanu, D., Pekkala, T., Silvennoinen, O., & Haan, S. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0891-8_2 · Cited by 5
“The hallmark of the family is the C-terminal SOCS-box that possesses Ubiquitin E3 ligase activity, and hyperphosphorylated forms of oncogenic or normal JAKs have been shown to become ubquitinated by SOCS and directed for proteasomal degradation (Kamizono et al. 2001; Ungureanu et al. 2002).”
BackgroundDemethylation of SOCS1 mediates its abnormally high expression in ovarian cancer
Li, X., Kong, C., Fan, Y.-C., Liu, J., Lu, W., Meng, C., Li, A., Zhai, A., Yan, B., Song, W., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10451 · Cited by 4
“bound protein via the proteasome-dependent pathway (21).”
Sukegawa, S., Sakuma, R., Ohmine, S., Takeuchi, H., Ikeda, Y., & Yamaoka, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109640 · Cited by 4
The JAK–STAT–SOCS Signaling Cascade
Murphy, J. M., Babon, J. J., Nicola, N. A., & Nicholson, S. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30016-5 · Cited by 4
Suppressor of cytokine signaling 1 inhibition strategy to enhance anti-HIV vaccination
Song, X., Aldrich, M. B., & Chen, S.-Y. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.4.495 · Cited by 5
Role of SOCS proteins in inflammation and autoimmune diseases
Fukaya, T., Suzuki, M., Sakaguchi, R., Yasukawa, H., & Yoshimura, A. (2011) · Inflammation and Regeneration · doi:10.2492/inflammregen.31.382 · Cited by 3
Self-citationMorichika, K., Karube, K., Sakihama, S., Watanabe, R., Kawaki, M., Nishi, Y., Nakachi, S., Okamoto, S., Takahara, T., Satou, A., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001691 · Cited by 3
“01 Ann Arbor stage ≥ III 18 (20) 65 (57) 0.”
Activation of Janus Kinases During Tumorigenesis
Schmidt, J. W., & Wagner, K. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0891-8_15 · Cited by 3
Hwang, J. Y., Holland, J. E., Valenteros, K. B., Sun, Y., Usherwood, Y.-K., Veríssimo, A. F., McLellan, J. S., Grigoryan, G., & Usherwood, E. J. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1800075 · Cited by 3
“Bound protein is also targeted for ubiquitination by the recruitment of elongins B and C and Cullin5 by the SH2 domain, leading to protein degradation (20, 22, 23).”
Santharam, M. A., Shukla, A., Ihsan, A. U., Cloutier, M., Lévesque, D., Ramanathan, S., Boisvert, F., & Ilangumaran, S. (2020) · Biochimie · doi:10.1016/j.biochi.2021.01.012 · Cited by 3
RING Fingers and Relatives: Determinators of Protein Fate
Lorick, K. L., Tsai, Y. C., Yang, Y., & Weissman, A. M. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch4 · Cited by 3
Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies
de Lima, S. C. G., Fantacini, D. M. C., Furtado, I. P., Rossetti, R., Silveira, R. M., Covas, D. T., & de Souza, L. E. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-33325-5_6 · Cited by 2
SOCS1 deficiency—crossroads of autoimmunity and autoinflammation—two case reports
Trojovsky, K., Seidl, M., Babor, F., Ehl, S. R., Lee‐Kirsch, M. A., Friedt, M., Laws, H.-J., Naami, N., Oommen, P. T., & Ghosh, S. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1516017 · Cited by 2
“SOCS1 in particular, has the ability, not only to help to catalyze the ubiquitination of signaling intermediates, but also to directly inhibit the JAK protein activity, predominantly the activity of JAK-2 (1, 4).”
Epigenetics in migraine: A review
Kumar, P., Sudershan, A., Bharti, S., Sheikh, J. H., Wani, S. A., & Kumar, H. (2023) · IP Indian Journal of Neurosciences · doi:10.18231/j.ijn.2023.026 · Cited by 4
Evolutionary Conserved Regulatory Mechanisms of the Jak/Stat Pathway
Grönholm, J. (2012) · Tampere University Institutional Repository (Tampere University) · Cited by 2
Role of receptor ubiquitination in erythropoietin receptor signaling
Mayuzumi, D. (2010) · doi:10.17077/etd.q6t85ext · Cited by 2
“However, not only EpoR but also other downstream effectors such as Jak2, Stat5, PI3 kinase and Akt are targets for ubiquitin-mediated degradation (Chen et 21 al., 2006; Fang et al., 2001; Kamizono et al., 2001; Suizu et al., 2009).”
Iatsiuk, V., Malinka, F., Pícková, M., Turečková, J., Kléma, J., Špoutil, F., Novosadová, V., Procházka, J., & Sedláček, R. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02265-2 · Cited by 1
“These genes are responsible for negative regulation of cytokine signaling through the JAK/STAT3 pathway, and was mentioned as a probable substrate recognition component of a SCF-like ECS E3 ubiquitin-protein ligase complex [28, 29].”
BackgroundJanus Kinase Inhibitors in Treatment of Primary Immune Regulatory Disorders
Alsaati, N., & Satter, L. F. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.05.019 · Cited by 1
Li, W., Liu, Y., Zhang, H., Zhang, H., Shao, W., Hu, T., Liao, Y., Zhang, W., & Kang, X. (2026) · Biology Direct · doi:10.1186/s13062-026-00974-2 · Cited by 1
STAT/SOCS Family Members in Inflammation and Diseases
Yoshimura, A., Kinjyo, I., Inagaki‐Ohara, K., & Hanada, T. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_34 · Cited by 1
Self-citationHollar, D. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100955 · Cited by 1
The Janus Kinase Protein Family
Saharinen, P., & Silvennoinen, O. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_3 · Cited by 1
Post-translational Modifications in Regulation of Jak-stat Pathway
Ungureanu, D. (2005) · Tampere University Institutional Repository (Tampere University) · Cited by 1
SOCS Proteins and Cytokine Signalling: The many Faces of the SOCS Box
Piessevaux, J. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 1
Negative Regulation of the JAK/STAT Signaling Pathway
Eyles, J. L., & Hilton, D. J. (2003) · Elsevier eBooks · doi:10.1016/b978-012124546-7/50436-8 · Cited by 2
Studies on the mechanisms of action and physiological relevance of SOCS proteins
Zadjali, F. (2011) · Figshare
Negative Regulation of Growth Hormone (GH) Signaling
Rico-Bautista, E. (2005) · Figshare
SCF Complex E3 Ubiquitin Ligases as Anticancer Targets
Jia, L., & Sun, Y. (2011)
The Jak-Stat Pathway of Cytokine Signaling
Croker, B. A., & Nicola, N. A. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-747-5_3
The Role of the Src-like Adaptor Protein in the Regulation of GM-CSFR Signaling
Clemente, S. D. (2014) · TSpace (University of Toronto)
Hörtner, M., & Heinrich, P. C. (2002) · RWTH Publications (RWTH Aachen)
Small Molecule Inhibitors and Inflammatory Skin Diseases
Omar, H. H. (2018) · Suez Canal University Medical Journal · doi:10.21608/scumj.2018.43336
Herzberg, C. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7706
In Vivo Role of Hepatic JAK2 and IGF-1 in Atherosclerosis
Sivasubramaniyam, T. (2018) · TSpace (University of Toronto)
Garg, S., Kumar, S., Anand, A., Menon, T., Sharma, N., Singh, J., Chawla, S., & Das, A. (2022) · Vegetos · doi:10.1007/s42535-021-00329-4
Faculty Opinions recommendation of Negative regulation of cytokine signaling in immunity.
Weiss, M. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727818654.793577762
The JAK–STAT–SOCS Signaling Cascade
Murphy, J. M., Babon, J. J., Nicola, N. A., & Nicholson, S. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.30016-5
Saudemont, A., Hamrouni, A., Marchetti, P., 刘继中, Jouy, N., Hétuin, D., Colucci, F., & Quesnel, B. (2023) · doi:10.1158/0008-5472.c.6495510
Investigating the role of SOCS1 in asthma exacerbations
Strong, K. (2019) · Spiral (Imperial College London) · doi:10.25560/85501
Iatsiuk, V., Malinka, F., Pícková, M., Turečková, J., Kléma, J., Špoutil, F., Novosadová, V., Prochazka, J., & Sedlacek, R. (2022) · Figshare · doi:10.6084/m9.figshare.19586878
Iatsiuk, V., Malinka, F., Pícková, M., Turečková, J., Kléma, J., Špoutil, F., Novosadová, V., Prochazka, J., & Sedlacek, R. (2022) · Figshare · doi:10.6084/m9.figshare.19586887
Qing, X., Tan, G.-L., Liu, H.-W., Li, W., Ai, J.-G., Xiong, S.-S., Yang, M.-Q., & Wang, T.-S. (2020) · Figshare · doi:10.6084/m9.figshare.12858746
Metadata
- Authors
- Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., Kitamura, T., Kato, H., Nakayama, K.-I., & Yoshimura, A.
- Affiliations
- Kurume University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Corresponding author
- Yoshimura, Akihiko
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 276
- Issue
- 16
- Pages
- 12530-12538
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2124489640
- Cited by
- 311
- References
- 38
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 10 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 11 · 2013: 8 · 2012: 22
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7127 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- SOCS1, SOCS box, ubiquitin-mediated proteolysis, E3 ubiquitin ligase, CUL2, JAK2 tyrosine kinase, leukemia, ubiquitination, SH2 domain, apoptosis
- MeSH terms
- Suppressor of Cytokine Signaling 1 Protein, Elongin, ETS Translocation Variant 6 Protein, Animals, Binding Sites, Carrier Proteins, Cell Division, Cell Line, Chromosomes, Human, Pair 12, Chromosomes, Human, Pair 9, Humans, Kinetics, Leukemia, Phosphorylation, Recombinant Fusion Proteins, Recombinant Proteins, Repressor Proteins, Transcription Factors, Transfection, Ubiquitins, Oncogene Proteins, Fusion, Mutagenesis, Cell Cycle Proteins, src Homology Domains, Cullin Proteins, Intracellular Signaling Peptides and Proteins, Suppressor of Cytokine Signaling Proteins, Mice, Janus Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.